Greenleaf Trust Has $1.70 Million Stake in Novartis AG (NVS)

Greenleaf Trust lifted its stake in shares of Novartis AG (NYSE:NVS) by 83.3% in the third quarter, HoldingsChannel reports. The institutional investor owned 19,729 shares of the company’s stock after purchasing an additional 8,966 shares during the period. Greenleaf Trust’s holdings in Novartis were worth $1,700,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in the company. Guggenheim Capital LLC lifted its stake in Novartis by 2.7% during the first quarter. Guggenheim Capital LLC now owns 43,471 shares of the company’s stock worth $3,515,000 after purchasing an additional 1,138 shares during the last quarter. Summit Trail Advisors LLC lifted its stake in Novartis by 24.1% during the first quarter. Summit Trail Advisors LLC now owns 23,020 shares of the company’s stock worth $1,483,000 after purchasing an additional 4,473 shares during the last quarter. Cardinal Capital Management Inc. lifted its stake in Novartis by 2.0% during the second quarter. Cardinal Capital Management Inc. now owns 90,916 shares of the company’s stock worth $6,868,000 after purchasing an additional 1,797 shares during the last quarter. Stonebridge Capital Management Inc. lifted its stake in Novartis by 1.8% during the second quarter. Stonebridge Capital Management Inc. now owns 52,765 shares of the company’s stock worth $4,061,000 after purchasing an additional 924 shares during the last quarter. Finally, Peachtree Investment Advisors Inc. lifted its stake in Novartis by 13.8% during the second quarter. Peachtree Investment Advisors Inc. now owns 10,055 shares of the company’s stock worth $760,000 after purchasing an additional 1,220 shares during the last quarter. 10.94% of the stock is owned by institutional investors and hedge funds.

Shares of NYSE NVS opened at $86.63 on Wednesday. The company has a debt-to-equity ratio of 0.29, a current ratio of 1.20 and a quick ratio of 0.96. Novartis AG has a twelve month low of $72.30 and a twelve month high of $94.19. The company has a market capitalization of $197.66 billion, a price-to-earnings ratio of 18.01, a PEG ratio of 1.90 and a beta of 0.83.



Novartis (NYSE:NVS) last issued its quarterly earnings data on Thursday, October 18th. The company reported $1.32 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.31 by $0.01. Novartis had a return on equity of 15.81% and a net margin of 25.98%. The company had revenue of $12.78 billion during the quarter, compared to analysts’ expectations of $12.88 billion. During the same quarter in the previous year, the business earned $1.29 earnings per share. The firm’s revenue for the quarter was up 2.9% on a year-over-year basis. As a group, sell-side analysts anticipate that Novartis AG will post 5.17 earnings per share for the current year.

NVS has been the subject of several recent analyst reports. Zacks Investment Research upgraded Novartis from a “hold” rating to a “buy” rating and set a $95.00 target price for the company in a research note on Tuesday, September 18th. Citigroup upgraded Novartis from a “neutral” rating to a “buy” rating in a research note on Tuesday, September 11th. Bank of America upgraded Novartis from an “underperform” rating to a “buy” rating and set a $74.71 target price for the company in a research note on Monday, September 10th. Exane BNP Paribas upgraded Novartis from an “underperform” rating to a “neutral” rating in a research note on Tuesday, September 11th. Finally, BNP Paribas upgraded Novartis from an “underperform” rating to a “neutral” rating in a research note on Tuesday, September 11th. Twelve analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Novartis presently has an average rating of “Hold” and a consensus price target of $84.86.

About Novartis

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines.

Recommended Story: Price to Earnings Ratio (PE) Basics

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply